Pfizer inks another RNA research agreement
Pfizer announces Jan. 3 a non-exclusive licensing agreement with Sigma-Aldrich for access to company's DNA-directed RNAi technology. According to Sigma-Aldrich, ddRNAi has advantages over other RNAi therapies, including a wider range of ways to deliver molecules into a target cell, the ability to simultaneously disable multiple genes and the ability to control the expression and timing of gene silencing. The Sigma-Aldrich deal is the second RNAi licensing agreement for Pfizer in the last six months. In September, Pfizer gained a worldwide license for Quark Biotech's RTP-801 gene, which targets wet age-related macular degeneration. Merck has also been actively investing in RNAi technology with the recent acquisitions of Sirna and Artemis...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.